Skip to main content

Table 3 Factors associated with survival outcomes in patients with endometrioid histologic type of uterine corpus endometrial carcinoma

From: LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data

Characteristics Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P HR 95% CI P Adjusted HR 95% CI P
Age, years
 ≥ 63 1.712 0.773–3.790 0.185 2.044 0.887–4.710 0.093 1.617 0.859–3.045 0.137 1.853 0.955–3.595 0.068
 < 63 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
Grade
 G3 3.041 1.379–6.704 0.006 1.817 0.768–4.302 0.174 1.322 0.702–2.489 0.388 0.889 0.452–1.746 0.733
 G1,2 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
FIGO stage
 III-IV 4.780 2.175–10.506 < 0.001 4.400 1.870–10.354 0.001 3.402 1.762–6.567 < 0.001 4.049 2.013–8.146 < 0.001
 I-II 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
LYL1 status
 Amplification 2.650 0.355–19.775 0.342 2.823 0.354–22.531 0.327 3.443 0.826–14.347 0.089 4.093 0.926–18.102 0.063
 Non-amplification 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref)
  1. Abbreviations: HR hazard ratio, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics